| 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. | |
| | |
MedLine Citation:
|
PMID: 12397467 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Melanoma is a neoplasia of dramatically increasing incidence that has a propensity to spread rapidly. Early detection is fundamental and patient management requires reliable, sensitive and reproducible staging methods, such as a single examination by planar scintigraphy or single-photon emission tomography (SPET) using a radiopharmaceutical with selectivity for melanoma tissue. Among iodobenzamides reported to possess an affinity for melanoma, a new compound, N-(2-diethylaminoethyl)-2-iodobenzamide (BZA(2)), was selected for a clinical trial in view of its pharmacokinetic experimental profile in melanoma-bearing mice. Planar whole-body scintigraphy using (123)I-BZA(2) was performed in 25 patients with histologically proven cutaneous melanoma. Performance was evaluated in two groups of patients with one or more documented secondary lesions ( n=13) or with no known secondary lesions ( n=12), and results were compared with those of conventional investigation techniques. No adverse clinical or biological events were recorded. Lesions were imaged by increased tracer uptake, and good quality images were obtained 4 h after administration. After a follow-up of more than 1 year, the overall results of (123)I-BZA(2) scintigraphy on a per patient basis showed a sensitivity of 100%, a specificity of 95%, a positive predictive value of 86% and a negative predictive value of 100%. The proven secondary lesions were imaged with a sensitivity of 100% and a specificity of 91%. In seven patients with suspected metastases, the absence of (123)I-BZA(2) uptake was confirmed as true negative, and in one patient without suspected metastases, (123)I-BZA(2) scintigraphy revealed a gastric lesion. Hence eight diagnoses would have been modified by (123)I-BZA(2) scintigraphy data. (123)I-BZA(2) allowed discrimination between benign and malignant lesions and, in the case of malignancies, between those of melanomatous origin and others. This compound, which is selective for melanoma tissue, appears promising for the staging and restaging of melanoma. |
| | |
Authors:
|
Nicole Moins; Michel D'Incan; Jacques Bonafous; Franck Bacin; Pierre Labarre; Marie-France Moreau; Danièle Mestas; Elisabeth Noirault; Florence Chossat; Eric Berthommier; Janine Papon; Martine Bayle; Pierre Souteyrand; Jean-Claude Madelmont; Annie Veyre |
Related Documents
:
|
16423207 - Positron emission tomography with ct in the evaluation of non-small cell lung cancer in... 21049467 - The role of pet-ct scan with somatostatin analogue labelled with gallium-68 ((68)ga-dot... 19544537 - The diagnostic and prognostic utility of positron emission tomography/computed tomograp... 1545657 - Positron emission tomography: a new, precise imaging modality for detection of primary ... 14523967 - Ringlet motion correction for 3d mri acquired with the elliptical centric view order. 8537897 - Isolation and characterization of two major degradation products of dyclonine hydrochlo... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Validation Studies Date: 2002-09-11 |
Journal Detail:
|
Title: European journal of nuclear medicine and molecular imaging Volume: 29 ISSN: 1619-7070 ISO Abbreviation: Eur. J. Nucl. Med. Mol. Imaging Publication Date: 2002 Nov |
Date Detail:
|
Created Date: 2002-10-24 Completed Date: 2003-07-24 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101140988 Medline TA: Eur J Nucl Med Mol Imaging Country: Germany |
Other Details:
|
Languages: eng Pagination: 1478-84 Citation Subset: IM |
Affiliation:
|
UMR 484 INSERM-Université d'Auvergne, Centre Jean Perrin, Rue Montalembert, BP 184, 63005 Clermont-Ferrand, France. moins@inserm484.u-clermont1.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Benzamides / blood, diagnostic use*, pharmacology, urine Feasibility Studies Female Humans Male Melanoma / diagnosis, metabolism, radionuclide imaging*, secondary* Middle Aged Neoplasm Staging / methods* Radiopharmaceuticals / diagnostic use Reproducibility of Results Sensitivity and Specificity Skin Neoplasms / diagnosis, metabolism, radionuclide imaging* Tomography, Emission-Computed, Single-Photon / methods |
| Chemical | |
Reg. No./Substance:
|
0/Benzamides; 0/N-(2-(diethylamino)ethyl)-2-iodobenzamide; 0/Radiopharmaceuticals |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematolo...
Next Document: Amino acid uptake in the skeletal muscle measured using [11C]methylaminoisobutyrate (MEAIB) and PET.